Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications

Hiddo J. L. Heerspink, Bruce A. Perkins, David H. Fitchett, Mansoor Husain, David Z. I. Cherney*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

486 Citations (Scopus)

Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight. Perhaps more important are the osmotic diuretic and natriuretic effects contributing to plasma volume contraction, and decreases in systolic and diastolic blood pressures by 4 to 6 and 1 to 2 mm Hg, respectively, which may underlie cardiovascular and kidney benefits. SGLT2 inhibition also is associated with an acute, dose-dependent reduction in estimated glomerular filtration rate by approximate to 5 mL.min(-1).1.73 m(-2) and approximate to 30% to 40% reduction in albuminuria. These effects mirror preclinical observations suggesting that proximal tubular natriuresis activates renal tubuloglomerular feedback through increased macula densa sodium and chloride delivery, leading to afferent vasoconstriction. On the basis of reduced glomerular filtration, glycosuric and weight loss effects are attenuated in patients with chronic kidney disease (estimated glomerular filtration rate 30% reductions in cardiovascular mortality, overall mortality, and heart failure hospitalizations associated with empagliflozin, even though, by design, the hemoglobin A1c difference between the randomized groups was marginal. Aside from an increased risk of mycotic genital infections, empagliflozin-treated patients had fewer serious adverse events, including a lower risk of acute kidney injury. In light of the EMPA-REG OUTCOME results, some diabetes clinical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic targets and who have prevalent atherosclerotic cardiovascular disease. With additional cardiorenal protection trials underway, sodium-related physiological effects of SGLT2 inhibitors and clinical correlates of natriuresis, such as the impact on blood pressure, heart failure, kidney protection, and mortality, will be a major management focus.

Original languageEnglish
Pages (from-to)752-772
Number of pages21
JournalCirculation
Volume134
Issue number10
DOIs
Publication statusPublished - 6-Sep-2016

Keywords

  • cardiovascular diseases
  • heart failure
  • sodium-glucose transporter 2
  • ATRIAL-NATRIURETIC-PEPTIDE
  • GLOMERULAR-FILTRATION-RATE
  • PLACEBO-CONTROLLED TRIAL
  • PROXIMAL TUBULAR CELLS
  • ALL-CAUSE MORTALITY
  • ADD-ON THERAPY
  • BLOOD-PRESSURE
  • ARTERIAL STIFFNESS
  • HEART-FAILURE
  • DOUBLE-BLIND

Cite this